Sunday, May 27, 2018
 
 
Company News: Page (1) of 1 - 05/15/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Palladium Equity Partners Completes Sale of Jordan Health Services
 
(May 15, 2018)

NEW YORK and DALLAS, May 15, 2018 /PRNewswire/ -- Palladium Equity Partners, LLC (along with its affiliates, "Palladium"), a private investment firm with more than $2.7 billion in assets under management, today announced that affiliates of the firm have completed the sale of the parent of Jordan Health Services ("Jordan"), one of the nation's largest home care providers, to Kelso & Company and Blue Wolf Capital Partners.

With the completion of the sale, Jordan is being combined with Great Lakes Caring and National Home Health Care to create one of the nation's largest home-based care providers. The new company, which brings together three market leaders and creates a comprehensive care continuum of personal care, skilled home healthcare, and hospice care, will serve more than 63,000 patients and their families daily, employing over 31,000 caregivers across 15 states in 221 locations.  

Following its acquisition of Jordan in December 2010, Palladium implemented key elements of its GOL value creation framework, focusing on Jordan's growth, operations and leadership. Palladium assisted in the recruitment of senior team members and the build out of an in-house M&A team, supported the company's investment in corporate infrastructure and diversification into new business lines and helped facilitate more than 30 acquisitions. Jordan's related organic growth initiatives and its M&A program expanded the company's service offerings, allowing the company to achieve geographic scale and lead the consolidation in its markets. As a result of these initiatives, Jordan grew into a leading provider of home health and hospice services to approximately 39,000 patients throughout the states of Texas, Oklahoma, Arkansas, Louisiana and Missouri.



About Palladium Equity Partners, LLC

Palladium is a middle market private equity firm with more than $2.7 billion of assets under management. The firm seeks to acquire and grow companies in partnership with founders and experienced management teams by providing capital, strategic guidance and operational oversight. Since its founding in 1997, Palladium has invested approximately $1.9 billion of capital in 30 platform investments and more than 100 add-on acquisitions. The firm focuses primarily on buyout equity investments in the range of $50 million to $150 million. The principals of the firm have significant experience in consumer, services, industrials, and healthcare businesses, with a special focus on companies they believe will benefit from the growth in the U.S. Hispanic population. Palladium is based in New York City. For more information, visit www.palladiumequity.com.

Media Contact for Palladium Equity Partners: 

Todd Fogarty, KEKST, [email protected], 212-521-4854

Cision View original content:http://www.prnewswire.com/news-releases/palladium-equity-partners-completes-sale-of-jordan-health-services-300648808.html

SOURCE Palladium Equity Partners, LLC

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA,Jordan,Science,Medical,Business,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Bellevue Asset Management AG: Bellevue launches dedicated digital health fund
  • Global Chromatography Reagents Market Analysis, Growth, Trends & Forecast 2018-2023, With The Market Forecasted to Register a CAGR of More Than 7% - ResearchAndMarkets.com
  • Life Science Reagents Market to exceed US$ 67.0 Bn by 2026, Says TMR
  • Study on Poor Oral Hygiene Habits of Aging Population Underlines the Importance of Outstanding Dental Care, says Premier Care Dental Group
  • Blood Gas and Electrolyte Analyzer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2023

    Cancer
  • Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1
  • NASP Applauds Bipartisan Legislation Introduced to Reduce Drug Costs and Support Access for Seniors with Life-Threatening Specialized Conditions
  • Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
  • Moorestown Visiting Nurse Association joins the growing enTouch network in New Jersey
  • Achieve Life Sciences, Inc. Announces Reverse Stock Split
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines